ReviewNature reviews. Gastroenterology & hepatology2012
Paradoxical inflammation induced by anti-TNF agents in patients with IBD.
Review in Nature reviews. Gastroenterology & hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort - APRIL Cohort
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 188 citations in OpenAlex.
- Risk Factors and Outcomes of Immunoglobulin A Vasculitis in Patients with Inflammatory Bowel Disease and vice versa: A Systematic Review of the current literature.Current gastroenterology reports · 2026Pooled it
- Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Fulminant Eosinophilic Myocarditis After Sequential Biologic Therapy in Ulcerative Colitis.JACC. Case reports · 2026Article
- Macrophage Plasticity: Phenotypic and Functional Profiles Across Pathological Microenvironments.International journal of molecular sciences · 2026Review
- Adalimumab-Induced Pyodermatitis-Pyostomatitis Vegetans (PPV) in Ulcerative Colitis: A Rare Dermatological Dilemma.Cureus · 2026Article
- TNF Inhibitor-Induced Sarcoidosis-Like Lesions in Inflammatory Bowel Disease.United European gastroenterology journal · 2026Article
- Rheumatoid Arthritis That Developed in a Patient with Ulcerative Colitis During Adalimumab Therapy: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2025Review
- Fundamental and emerging insights into innate and adaptive immunity in inflammatory bowel diseases.Frontiers in immunology · 2025Review
- Identification and validation of shared biomarkers and drug repurposing in psoriasis and Crohn's disease: integrating bioinformatics, machine learning, and experimental approaches.Frontiers in immunology · 2025Article
- Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Review
- Plant-Derived Bioactive Compounds: Exploring Neuroprotective, Metabolic, and Hepatoprotective Effects for Health Promotion and Disease Prevention.Pharmaceutics · 2024Review
- New, Old, and Shared Antibody Specificities in Autoimmune Diseases.Antibodies (Basel, Switzerland) · 2024Article
- Ustekinumab as a Treatment for Ixekizumab-Associated New-Onset Crohn's Disease in a Patient with Psoriasis.ACG case reports journal · 2024Article
- 18F-FDG-PET and other imaging modalities in the diagnosis and management of inflammatory bowel disease.American journal of nuclear medicine and molecular imaging · 2024Review
- A Case of Paradoxical Arthralgia Following Anti-TNF Monoclonal Antibody Administration in a Patient With New-Onset Pediatric Crohn's Disease.JPGN reports · 2023Article
- Myelolipoma After Infliximab Treatment for Crohn's Disease.ACG case reports journal · 2022Article
- Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases.Deutsches Arzteblatt international · 2022Article
- Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF.RMD open · 2022Article
- Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy.Frontiers in cellular and infection microbiology · 2022Article
- Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy.Therapeutic advances in gastroenterology · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-TNF antibodies have acquired a prominent place in the management of IBD (including Crohn's disease and ulcerative colitis), rheumatologic conditions (such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis) and psoriasis. They have a good safety profile, especially when contraindications such as demyelinating disease, active infections and/or abscesses are ruled out, and when necessary precautions to prevent reactivation of tuberculosis are taken. However, with increasing use of these agents, paradoxical adverse events have been reported. Some of these features are shared with the underlying disease for which these drugs are given, making management of these conditions challenging. For example, anti-TNF therapy is used for the treatment of psoriasis, but psoriasiform lesions are sometimes observed in patients receiving therapy. Similarly, anti-TNF therapy is used for the treatment of rheumatologic diseases, but arthralgias and arthritis are sometimes observed in patients receiving anti-TNF agents. We review the paradoxical inflammation induced by anti-TNF agents in patients with IBD, provide hypotheses for the occurrence of this paradoxical inflammation and give practical advice on how to manage these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.